{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:41Z","timestamp":1791920861066,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K08AI134262"],"award-info":[{"award-number":["K08AI134262"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI055433"],"award-info":[{"award-number":["T32AI055433"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS108344"],"award-info":[{"award-number":["R21NS108344"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS086312"],"award-info":[{"award-number":["R01NS086312"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"crossref","award":["K01TW010268"],"award-info":[{"award-number":["K01TW010268"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["R25TW009345"],"award-info":[{"award-number":["R25TW009345"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["M007413\/1"],"award-info":[{"award-number":["M007413\/1"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Management of co-infections including cryptococcal meningitis, tuberculosis and other opportunistic infections in persons living with HIV can lead to complex polypharmacotherapy and increased susceptibility to drug-drug interactions (DDIs). Here we characterize the frequency and types of potential DDIs (pDDIs) in hospitalized HIV patients presenting with suspected cryptococcal or tuberculous meningitis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In a retrospective review of three cryptococcal meningitis trials between 2010 and 2017 in Kampala, Uganda, medications received over hospitalization were documented and pDDI events were assessed. IBM Micromedex DRUGDEX\u00ae online drug reference system was used to identify and describe potential interactions as either contraindicated, major, moderate or minor. For antiretroviral DDIs, the Liverpool Drug Interactions Checker from the University of Liverpool was also used to further describe interactions observed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In 1074 patients with suspected meningitis, pDDIs were present in 959 (overall prevalence\u2009=\u200989.3%) during the analyzed 30\u2009day window. In total, 278 unique interacting drug pairs were identified resulting in 4582 pDDI events. Of all patients included in this study there was a mean frequency of 4.27 pDDIs per patient. Of the 4582 pDDI events, 11.3% contraindicated, 66.4% major, 17.4% moderate and 5% minor pDDIs were observed. Among all pDDIs identified, the most prevalent drugs implicated were fluconazole (58.4%), co-trimoxazole (25.7%), efavirenz (15.6%) and rifampin (10.2%). Twenty-one percent of the contraindicated pDDIs and 27% of the major ones involved an antiretroviral drug. Increased likelihood of QT interval prolongation was the most frequent potential clinical outcome. Dissonance in drug interaction checkers was noted requiring clinicians to consult more than one database in making clinical decisions about drug combinations.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The overall prevalence of pDDIs in this population is high. An understanding of drug combinations likely to result in undesired clinical outcomes, such as QT interval prolongation, is paramount. This is especially important in resource limited settings where availability of therapeutic drug monitoring and laboratory follow-up are inconsistent. Adequate quantification of the increased likelihood of adverse clinical outcomes from multiple drug-drug interactions of the same kind in a single patient is needed to aid clinical decisions in this setting.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05296-w","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T09:03:02Z","timestamp":1596618182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda"],"prefix":"10.1186","volume":"20","author":[{"given":"Prosperity C.","family":"Eneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Huppler","family":"Hullsiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kiiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Rhein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Meya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Boulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-5509","authenticated-orcid":false,"given":"Melanie R.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"5296_CR1","doi-asserted-by":"crossref","unstructured":"Kr\u00e4henb\u00fchl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Kr\u00e4henb\u00fchl S. Drug-related problems in hospitals. Drug Saf. 2007;30:379\u2013407\u00a0 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17472418.","DOI":"10.2165\/00002018-200730050-00003"},{"key":"5296_CR2","doi-asserted-by":"crossref","unstructured":"Mizokami F, Koide Y, Noro T, Furuta K. Polypharmacy with common diseases in hospitalized elderly patients. Am J Geriatr Pharmacother. 2012;10:123\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22387105.","DOI":"10.1016\/j.amjopharm.2012.02.003"},{"key":"5296_CR3","doi-asserted-by":"crossref","unstructured":"Becker ML, Kallewaard M, Caspers PWJ, Visser LE, Leufkens HGM, Stricker BHC. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641\u201351. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17154346.","DOI":"10.1002\/pds.1351"},{"key":"5296_CR4","doi-asserted-by":"crossref","unstructured":"Van Den Bemt PMLA, Egberts ACG, Lenderink AW, Verzijl JM, Simons KA, Van Der Pol WSCJM. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22:62\u20136. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10849925.","DOI":"10.1023\/A:1008721321016"},{"key":"5296_CR5","doi-asserted-by":"crossref","unstructured":"Lafata JE, Schultz L, Simpkins J, Chan KA, Horn JR, Kaatz S, et al. Potential drugg-drug interactions in the outpatient setting. Med Care. 2006;44:534\u201341. Available from: https:\/\/www.jstor.org\/stable\/40221316.","DOI":"10.1097\/01.mlr.0000215807.91798.25"},{"key":"5296_CR6","doi-asserted-by":"crossref","unstructured":"Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother. 2009;64:5\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19398457.","DOI":"10.1093\/jac\/dkp152"},{"key":"5296_CR7","doi-asserted-by":"crossref","unstructured":"Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, Carey PB, et al. Recognition of risk for clinically significant drug interactions among hiv-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2010;50:1419\u201321. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20380564.","DOI":"10.1086\/652149"},{"key":"5296_CR8","doi-asserted-by":"crossref","unstructured":"Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61:675\u201381. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16047138.","DOI":"10.1007\/s00228-005-0978-6"},{"key":"5296_CR9","doi-asserted-by":"crossref","unstructured":"Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug\u2013drug interactions. Expert Opin Drug Saf. 2011;11:83\u201394. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22022824.","DOI":"10.1517\/14740338.2012.631910"},{"key":"5296_CR10","doi-asserted-by":"crossref","unstructured":"Seden K, Merry C, Hewson R, Siccardi M, Lamorde M, Byakika-Kibwika P, et al. Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. J Antimicrob Chemother. 2015;70:3317\u201322. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26286575.","DOI":"10.1093\/jac\/dkv259"},{"key":"5296_CR11","doi-asserted-by":"publisher","first-page":"e16800","DOI":"10.1371\/journal.pone.0016800","volume":"6","author":"G Kigen","year":"2011","unstructured":"Kigen G, Kimaiyo S, Nyandiko W, Faragher B, Sang E, Jakait B, et al. Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large kenyan cohort. PLoS One. 2011;6:e16800. https:\/\/doi.org\/10.1371\/journal.pone.0016800.","journal-title":"PLoS One"},{"key":"5296_CR12","doi-asserted-by":"crossref","unstructured":"Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487\u201398. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24963568.","DOI":"10.1056\/NEJMoa1312884"},{"key":"5296_CR13","doi-asserted-by":"crossref","unstructured":"Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016;16:809\u201318. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26971081.","DOI":"10.1016\/S1473-3099(16)00074-8"},{"key":"5296_CR14","unstructured":"Rhein J, Hullsiek KH, Evans EE, Tugume L, Nuwagira E, Ssebambulidde K, et al. Detrimental outcomes of unmasking cryptococcal meningitis with recent ART initiation. Open Forum Infect Dis. 2018;5(8):ofy122."},{"key":"5296_CR15","unstructured":"IBM Micromedex\u00ae DRUGDEX\u00ae [electronic version]. Truven Health Analytics GV, Colorado, USA."},{"key":"5296_CR16","doi-asserted-by":"crossref","unstructured":"Vonbach P, Dubied A, Kr\u00e4henb\u00fchl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30:367\u201374. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18415695.","DOI":"10.1007\/s11096-008-9191-x"},{"key":"5296_CR17","unstructured":"Liverpool HPGev. Cheshire. United Kingdom Univ Liverpool eMed- Fusion."},{"key":"5296_CR18","unstructured":"R Core Team R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2018. Available from: https:\/\/www.r-project.org\/."},{"key":"5296_CR19","unstructured":"Lubinga SJ, Uwiduhaye E. Potential drug-drug interactions on in-patient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in western Uganda: prevalence, clinical importance and associated factors. Afr Health Sci. 2011;11:499\u2013507. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22275946."},{"key":"5296_CR20","doi-asserted-by":"crossref","unstructured":"Bhagavathula AS, Berhanie A, Tigistu H, Abraham Y, Getachew Y, Khan TM, et al. Prevalence of potential drug\u2013drug interactions among internal medicine ward in University of Gondar Teaching Hospital, Ethiopia. Asian Pac J Trop Biomed. 2014;4:S204\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25183081.","DOI":"10.12980\/APJTB.4.2014C1172"},{"key":"5296_CR21","doi-asserted-by":"crossref","unstructured":"Ismail M, Iqbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, et al. Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013;35:455\u201362. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23483444.","DOI":"10.1007\/s11096-013-9764-1"},{"key":"5296_CR22","unstructured":"Mousavi S, Ghanbari G. Potential drug-drug interactions among hospitalized patients in a developing country. Casp J Intern Med. 2017;8:282\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29201319."},{"key":"5296_CR23","doi-asserted-by":"crossref","unstructured":"Gebretsadik Z, Gebrehans M, Getnet D, Gebrie D, Alema T, Belay YB. Assessment of drug-drug interaction in ayder comprehensive specialized hospital, Mekelle, Northern Ethiopia: a retrospective study. Biomed Res Int. 2017;2017:1\u20136. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29250554.","DOI":"10.1155\/2017\/9792363"},{"key":"5296_CR24","doi-asserted-by":"crossref","unstructured":"Srikanth BA, Admassie E, Hailu W, Melese T, Mequanent W. Extent of poly-pharmacy, occurrence and associated factors of drug-drug interaction and potential adverse drug reactions in Gondar Teaching Referral Hospital, North West Ethiopia. J Adv Pharm Technol Res. 2014;4:183. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24350048.","DOI":"10.4103\/2231-4040.121412"},{"key":"5296_CR25","doi-asserted-by":"crossref","unstructured":"Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc. 1996;44:944\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8708305.","DOI":"10.1111\/j.1532-5415.1996.tb01865.x"},{"key":"5296_CR26","doi-asserted-by":"crossref","unstructured":"Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12634985.","DOI":"10.1007\/s00228-002-0557-z"},{"key":"5296_CR27","doi-asserted-by":"publisher","unstructured":"Morales-R\u00edos O, Jasso-Guti\u00e9rrez L, Reyes-L\u00f3pez A, Gardu\u00f1o-Espinosa J, Mu\u00f1oz-Hern\u00e1ndez O. Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico. PLoS One. 2018;13:e0190882. https:\/\/doi.org\/10.1371\/journal.pone.0190882. Public Library of Science.","DOI":"10.1371\/journal.pone.0190882"},{"key":"5296_CR28","doi-asserted-by":"crossref","unstructured":"Tay KY, Ewald MB, Bourgeois FT. Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiol Drug Saf. 2014;23:9\u201317. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23696066.","DOI":"10.1002\/pds.3455"},{"key":"5296_CR29","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/j.1540-8159.1997.tb05439.x","volume":"20","author":"AG Kocheril","year":"1997","unstructured":"Kocheril AG, Bokhari SAJ, Batsford WP, Sinusas AJ. Long QT(c) and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol. 1997;20:2810\u20136.","journal-title":"Pacing Clin Electrophysiol"},{"key":"5296_CR30","first-page":"1657","volume":"97","author":"MU Sani","year":"2005","unstructured":"Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc. 2005;97:1657\u201361.","journal-title":"J Natl Med Assoc"},{"key":"5296_CR31","doi-asserted-by":"crossref","unstructured":"Nordin C, Kohli A, Beca S, Zaharia V, Grant T, Leider J, et al. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol. 2006;39:199\u2013205. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022073605002943.","DOI":"10.1016\/j.jelectrocard.2005.09.001"},{"key":"5296_CR32","unstructured":"Woosley RL, Heise CW, Gallo T, Woosley RD and Romero K. QTFactors [Internet]. AZCERT, Inc. 1822 Innov. Park Dr., Oro Val. AZ 85755. [cited 2020 Jun 19]. Available from: https:\/\/www.crediblemeds.org\/ndfa-list\/."},{"issue":"12","key":"5296_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/2045125317721662","volume":"7","author":"AD Meid","year":"2017","unstructured":"Meid AD, Bighelli I, M\u00e4chler S, Mikus G, Carr\u00e0 G, Castellazzi M, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251\u201364.","journal-title":"Ther Adv Psychopharmacol"},{"key":"5296_CR34","unstructured":"Velamakanni S, Kiggundu R, Rhein J, Butler EK, Meya DB, Boulware DR. Effect of adjunctive sertraline on QTc interval in patients with Cryptococcal meningitis. Mycoses. 2014;57:41."},{"key":"5296_CR35","doi-asserted-by":"crossref","unstructured":"Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3:37\u201349. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25755470.","DOI":"10.1016\/j.jceh.2012.12.001"},{"key":"5296_CR36","unstructured":"WHO | Global tuberculosis report 2017. WHO [Internet]. World Health Organization; 2017 [cited 2018 Jun 28]; Available from: http:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"5296_CR37","doi-asserted-by":"crossref","unstructured":"Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest. 1994;105:408\u201311. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7508362.","DOI":"10.1378\/chest.105.2.408"},{"key":"5296_CR38","doi-asserted-by":"crossref","unstructured":"Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, et al. Significant pharmacokinetic interactions between artemether\/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012;67(9):2213\u201321. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3465101\/pdf\/dks207.pdf.","DOI":"10.1093\/jac\/dks207"},{"key":"5296_CR39","unstructured":"Product Information. KLOR-CON(R) extended release tablets, potassium chloride extended release tablets. Minneapolis: Upsher Smith Laboratories, Inc. Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/019123s027lbl.pdf."},{"key":"5296_CR40","unstructured":"Product Information. REGLAN(R) oral tablets, metoclopramide oral tablets. Baudette: ANI Pharm. Inc. (per FDA). Last Revised August 2017. Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/017854s062lbl.pdf."},{"key":"5296_CR41","doi-asserted-by":"crossref","unstructured":"Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug-drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206\u201317. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25917055.","DOI":"10.1016\/j.jbi.2015.04.006"},{"key":"5296_CR42","doi-asserted-by":"crossref","unstructured":"Khalil V, Chin K, Tran M, Furtula D. The impact of pharmacists\u2019 input to reduce serotonin syndrome drug interactions in an Australian hospital. Int J Evid Based Healthc. 2016;14:123\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27552535.","DOI":"10.1097\/XEB.0000000000000091"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05296-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05296-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05296-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:18:02Z","timestamp":1628119082000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05296-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5296"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05296-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original trials that provided the data used for this analysis received written, informed patient consent and were approved by the Mulago Research Ethics committee, the Uganda National Council of Science and Technology and the National Drug Authority. Principal investigators of these trials (co-authors on this manuscript) granted permission to this dataset.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflicts of interest noted by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"572"}}